Neuroone Medical Technologies (NMTC) Research & Development (2017 - 2026)

Neuroone Medical Technologies (NMTC) has reported Research & Development for 10 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 20.52% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $5.4 million (up 8.47% YoY), and the FY2025 full-year result was $5.0 million, down 1.62% from the prior year.
• Research & Development retreated to $1.4 million in Q2 2026 per NMTC's latest filing, from $1.5 million in the prior quarter.
• Across five years, Research & Development topped out at $1.9 million in Q2 2023 and bottomed at $1.1 million in Q3 2024.
• Historically, Research & Development has averaged $1.4 million across 5 years, with a median of $1.4 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Research & Development soared 54.36% in 2023, then tumbled 37.41% in 2024.
• Over 5 years, Research & Development stood at $1.6 million in 2022, then declined by 5.13% to $1.5 million in 2023, then declined by 20.97% to $1.2 million in 2024, then gained by 18.55% to $1.4 million in 2025, then grew by 2.55% to $1.4 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.4 million, $1.5 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.